Notable 52-Week Highs and Lows of the Day 03/04: (LEI) (JNPR) (SPRD) High; (CEDC) (ALTH) Low

FREE Breaking News Alerts from StreetInsider.com!

March 4, 2011 2:07 PM EST

This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.

52-Week High:

Lucas Energy, Inc. (AMEX: LEI) high of $4.43. Seeing lots of buying today, continuing a stellar two-day move, which now has the stock up over 120% for the week. Volume is up on over 22x normal volume.
Juniper Networks, Inc. (Nasdaq: JNPR) high of $44.94. Up just 2.7% to the new 52-week high following an Analyst Day which evoked bullish sentiment from several top ratings firms. Most maintained their ratings on the stock, and a few increased their price targets. Ticonderoga liked "Juniper's iconoclastic view of how to build the "new network" that is supported by the company's aggressively expanding product portfolio." UBS commented that "Juniper's TAM opportunity is compelling going from $41B in 2010 to ~$64B in 2013 on ~$10B in market growth and $13B in portfolio expansion."
Spreadtrum Communications Inc. (Nasdaq: SPRD) high of . SPRD reported Q410 EPS of $0.61 on revs of $126.5 million, compared to the consensus EPS of $0.52 and revs of $122.23 million. Looking ahead, Spreadtrum sees Q111 revs of $130 - $135 million, ahead of the $109.29 million consensus. SPRD also received some bullish comments from several analysts today.
Dejour Enterprises, Ltd. (AMEX: DEJ) high of $0.53. Making a solid move north today, seeing the same buying action as Lucas Energy. With oil rising in price, shares might be able to get back to the high $1's and possibly $2 should positive sentiment continue.

52-Week Low:

Central European Distribution Corp. (Nasdaq: CEDC) low of $12.27. CEDC is seeing plenty of downside, about 12% as Credit Suisse cut their rating on the shares from Outperform to Underperform and slashing their price target 60% from $30 to $12. CEDC shares are down 45.7% since the start of March following the company's fourth quarter earnings results, reported on March 1st.
Allos Therapeutics, Inc. (Nasdaq: ALTH) low of $3.00. Initially starting off in positive territory today following a relatively strong Q4 earnings report, shares have since dropped to a new 52-week low of $3.00. Canaccord Genuity noted "uninspiring Folotyn sales growth and drain on capital resources." Needham & Company is "encouraged by the sequential sales growth Q/Q suggesting that the Company’s new commercial strategy may be taking hold by generating increased awareness of FOLOTYN..."

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!